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AbsTrACT
Objective regorafenib demonstrated efficacy in 
patients with metastatic colorectal cancer (mcrc). 
lack of predictive biomarkers, potential toxicities and 
cost-effectiveness concerns highlight the unmet need for 
better patient selection.
Design Patients with RAS mutant mcrc with 
biopsiable metastases were enrolled in this phase ii trial. 
Dynamic contrast-enhanced (Dce) Mri was acquired 
pretreatment and at day 15 post-treatment. Median 
values of volume transfer constant (Ktrans), enhancing 
fraction (eF) and their product KeF (summarised median 
values of Ktrans× eF) were generated. circulating tumour 
(ct) Dna was collected monthly until progressive disease 
and tested for clonal RAS mutations by digital-droplet 
Pcr. tumour vasculature (cD-31) was scored by 
immunohistochemistry on 70 sequential tissue biopsies.
results twenty-seven patients with paired Dce-Mri 
scans were analysed. Median KeF decrease was 58.2%. 
Of the 23 patients with outcome data, >70% drop in 
KeF (6/23) was associated with higher disease control 
rate (p=0.048) measured by reciSt V. 1.1 at 2 months, 
improved progression-free survival (PFS) (Hr 0.16 
(95% ci 0.04 to 0.72), p=0.02), 4-month PFS (66.7% 
vs 23.5%) and overall survival (OS) (Hr 0.08 (95% 
ci 0.01 to 0.63), p=0.02). KeF drop correlated with 
cD-31 reduction in sequential tissue biopsies (p=0.04). 
RAS mutant clones decay in ctDna after 8 weeks of 
treatment was associated with better PFS (Hr 0.21 (95% 
ci 0.06 to 0.71), p=0.01) and OS (Hr 0.28 (95% ci 
0.07–1.04), p=0.06).
Conclusions combining Dce-Mri and ctDna predicts 
duration of anti-angiogenic response to regorafenib and 
may improve patient management with potential health/
economic implications.
InTrODuCTIOn
Colorectal cancer (CRC) remains a major health 
burden with significant morbidity and mortality 
despite recent improvements in its management 
owing to better screening and therapeutic options.1 
CRC is known to be a biologically heterogeneous 
disease characterised by the activation of several 
angiogenic and oncogenic pathways.2 Regorafenib, 
a multikinase inhibitor with known anti-angio-
genic, antistromal and anti-oncogenic activi-
ties,3 has demonstrated single agent efficacy in 
patients with treatment refractory metastatic CRC 
(mCRC).4 5 The use of regorafenib in the clinic is 
however hampered by the modest efficacy in an 
unselected patient population, a significant side 
effect profile and the high drug costs. Consequently, 
identification of predictive biomarkers of response 
and resistance to regorafenib is critical for treatment 
stratification and appropriate patient selection such 
that treatment benefits could be optimised.
Several efforts are currently ongoing to define 
gene signatures6 and biomarkers of response to 
anti-angiogenic drug in CRC and other cancers7 ; 
however, validation of these biomarkers will only 
determine their use in clinical practice. While recent 
studies using tissue8 and plasma9 10 have attempted 
to elucidate the response and resistance mecha-
nisms to regorafenib, the search for a clinically 
useful biomarker has been largely unsuccessful. 
A growing body of preclinical evidence suggests 
strong anti-angiogenic and pro-apoptotic effects of 
regorafenib11–14 with clinical data demonstrating 
that drug activity is independent of the tumour’s 
mutational status.8 These findings strengthen the 
hypothesis that additional mechanisms other than 
oncogenic blockade are responsible for the antitu-
mour activity of this drug. Dynamic contrast-en-
hanced (DCE) MRI may have a useful role in 
evaluating tumour vascular heterogeneity and early 
anti-angiogenic effects15 16 ; moreover, its param-
eters volume transfer constant (Ktrans), enhancing 
fraction (EF) and initial area under the gadolinium 
concentration time curve over 60 s (IAUGC60) have 
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significance of the study
What is already known on this subject?
 ► Regorafenib is approved as third-line therapy for patients 
with refractory colorectal cancer ; however, its use in the 
clinic has been restricted due to modest clinical benefit in 
unselected patients.
 ► Published preclinical studies suggested that anti-angiogenic 
activity of regorafenib is the main predeterminant of its 
efficacy but no clinical studies have validated these findings.
 ► Retrospective analysis of prospective clinical trials failed to 
identify biomarkers of response to regorafenib that might be 
implemented in clinical practice.
What are the new findings?
 ► Regorafenib showed significant activity in patients with 
marked early anti-angiogenic response, resulting in a longer 
disease control, better progression-free survival and overall 
survival .
 ► Early (day 15 post-treatment) dynamic contrast enhanced 
(DCE)-MRI predicts response and long-term outcome during 
regorafenib treatment.
 ► Sequential analysis of tissue biopsies confirmed that 
reduction in tumour vasculature as the mechanism 
underpinning the observed radiological findings.
 ► Persistent regorafenib-induced anti-angiogenic effect 
translates into a reduction in circulating tumour (ct) DNA 
and this might be incorporated into the clinical algorithm for 
patients’ management.
Implications on clinical practice
Implementing the use of DCE-MRI and ctDNA analysis as early 
biomarkers of response to regorafenib might improve patient 
selection with clear health/economic implications for patients, 
health systems and society.
been correlated with microvessel density and in some tumours 
with degree of vascular endothelial growth factor (VEGF) 
expression.17 By contrast, diffusion-weighted MRI (DW-MRI) 
offers useful information that reflects tumour cellularity and 
increase in its quantitative parameter apparent diffusion coef-
ficient (ADC) has been associated with tumour cell death and 
necrosis.18 19 At least two preclinical studies demonstrated that 
regorafenib was able to significantly suppress tumour vascularity 
when quantified by DCE- computed tomography (CT) and MRI 
modalities respectively in human colon carcinoma xenograft 
models.14 20
In this prospective phase II trial of patients with RAS mutant 
mCRC treated with single agent regorafenib, we hypothesised 
that (1) an early anti-angiogenic and antiproliferative activity 
of regorafenib might be detected by multiparametric DCE-MRI 
on day 15 of the treatment, (2) the depth of anti-angiogenic 
response detected by a significant drop in DCE-MRI quantita-
tive parameters might correlate with clinical efficacy, (3) analysis 
of sequential tissue and liquid biopsies could be integrated into 
the biomarker discovery process and shed insights into mecha-
nisms of response to regorafenib.
MATerIAl AnD MeThODs
Clinical trial design
PROSPECT-R trial (clinical  trials. gov number (NCT03010722)) 
is a phase II, open label, non-randomised study of regorafenib 
in patients with RAS mutant, chemorefractory mCRC (figure 1). 
Patients who were at least 18 years old and had a WHO perfor-
mance status (PS) of 0–1 were deemed eligible if all conventional 
treatment options including fluorouracil, irinotecan, oxaliplatin 
and at least one anti-VEGF drugs (later trial protocol was 
amended due to changes in availability of anti-VEGF agents due 
to funding restrictions in UK) were exhausted; they had meta-
static tumour amenable to biopsy and repeat measurements with 
DCE-MRI. Written informed consent was obtained from all 
Figure 1 PROSPECT-R trial design. Patients meeting all inclusion and no exclusion criteria were required to have pretreatment CT, DCE-MRI and 
DW-MRI scans; MRI scans were then repeated on day 15. All patients were also required to have pretreatment mandatory core biopsy, followed by a 
core biopsy at 2 months if they had SD or PR. Patients were monitored by CT scans every 2 months until the time of PD and if clinically feasible, they 
had biopsy of one or two progressing lesions from PD sites. Plasma samples were collected every 4 weeks until the time of PD. ctDNA, circulating 
tumour DNA; DCE, dynamic contrast enhanced; DW, diffusion weighted; MRI, magnetic resonance imaging; PD, progressive disease; PR, partial 
response; SD, stable disease.
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patients. The study was carried out in accordance with the Decla-
ration of Helsinki and approved by National Institutional review 
boards (Medicines and Healthcare products Regulatory Agency: 
15983/0249/001–0001). All participants were required to have 
mandatory pretreatment biopsies (six cores targeted towards the 
MRI identified index lesion), biopsies at 2 months (if response 
or stable disease by RECIST V.1.1 criteria (six cores)) and at the 
time of progression (6–12 cores from two suitable progressing 
metastatic sites). Three out of six cores were snap-frozen; one 
core was used to establish patient- derived organoids and two 
cores were formalin fixed and paraffin embedded (FFPE).
The Results section describes the number of cores used for 
immunohistochemistry analysis in the current study. Further 
genomic, transcriptomic and functional analyses are ongoing 
on the remaining cores. Patients with suitable metastatic 
disease (defined as lesions at least 2 cm in diameter) and no 
contraindications to MRI underwent multiparametric MRI 
studies including matched DCE and DW; images were acquired 
<7 days prior to therapy and at day 15 post-treatment. Treat-
ment consisted of regorafenib 160 mg once daily on a schedule 
of 3 weeks on and 1 week off until progression or intolerable 
side effects. More details on inclusion and exclusion criteria and 
criteria for patients’ withdrawal on the study are provided in the 
online supplementary material.
MrI data processing
DCE-MRI data were postprocessed using the MRI Workbench 
software developed at our institution.21 The pharmacoki-
netic analysis was based on the extended Kety/Tofts model in 
conjunction with a cosine-based arterial input function model 
derived from population-averaged values.22 23 DCE-MRI 
parameters including Ktrans, IAUGC60 and the EF were obtained 
for pretreatment/post-treatment datasets. Ktrans estimates were 
reported for both whole tumour (Ktrans(all)) and valid voxels 
only (Ktrans(non-zeros), i.e. excluding all non-enhancements 
and non-model fits) in order to address the extended necrosis 
observed in the cohort. The EF was defined as percentage of 
the voxels that enhance above the noise floor out of all tumour 
voxels. A voxel was considered enhancing when its postcon-
trast (Dotarem, Guerbet, France) dynamic intensity signal was 
at least 1 standard deviation higher than the mean precontrast 
signal, for a period of 60 s postcontrast onset. Finally, volume 
change in tumour enhancement during therapy (such as new 
necrosis) was accounted for by reporting a composite param-
eter, KEF, which is the product of summarised median values 
of KEF= Ktrans (non-zeros) × EF.24 For KEF, an receiving oper-
ating charactteristic (ROC) curve analysis was performed to 
establish the cut-off able to identify meaningful clinical benefit 
based on disease control rate (DCR), progression-free survival 
(PFS) and overall survival (OS).
DIgITAl-DrOpleT pCr
The QX200 digital-droplet PCR (ddPCR) system (Bio-Rad, 
Berkeley, California, USA) was used, and all reactions were 
prepared using the ddPCR supermix with no dUTPTP for 
probes. All PCR reactions were performed as duplex PCR using 
the relevant digital PCR assays for the wild-type and the muta-
tion in question. Droplets were generated using the QX200 
droplet generator according to the manufacturer’s protocols. 
The PCR reaction was performed in a C1000 Touch Thermo 
Cycler (Bio-Rad) using the following protocol: 95°C for 10 min 
followed by 40 cycles of 94°C for 30 s and 55°C for 1 min, then 
98°C for 10 min. Droplets were read in the QX200 droplet 
reader and analysed using the Quantasoft software V. 1.6.6.0320 
Table 1 Baseline characteristics of participating patients
n %
Age, median (range) 63.7 (36.3–79.0)
Gender
  Female 10 37
  Male 17 63
Site of primary
  Rectal 7 26
  Left colon 9 33
  Right colon 11 41
Histology diagnosis
  Unknown 1 4
  Adeno (mucinous) 4 15
  Adeno (non-mucinous) 22 81
Stage diagnosis
  Stage II 5 19
  Stage III 5 19
  Stage IV 17 62
Radiotherapy to primary
  Yes 4 15
  No 23 85
Number of lines in metastatic setting
  1 1 4
  2 11 41
  3 9 33
  4 3 11
  5 2 7
  6 1 4
Figure 2 Outcome according to radiological parameters in the PROSPECT-R trial. Kaplan-Meier curves for progression-free survival (A) and overall 
survival (B) in patients with or without KEF drop. KEF, Ktrans× enhancing fraction.
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(Bio-Rad). Fractional abundance (FA) was defined as follows: 
FA % = (Nmut/(Nmut + Nwt))×100), where Nmut is the 
number of mutant events and Nwt is the number of WT events 
per reaction. The number of positive and negative droplets was 
used to calculate the concentration of the target and reference 
DNA sequences and their Poisson-based 95% CI. ddPCR anal-
ysis of normal control plasma DNA (from cell lines) and no 
DNA template controls were always included. Samples with 
very low positive events were repeated at least twice in indepen-
dent experiments to validate the obtained results as previously 
described.25
CD31, Ki-67 and Caspase-3 immunohistochemical staining
The immunohistochemical expression of microvascular 
density (CD31; clone ab28364, Abcam, Cambridge, UK; 
dilution 1:50), cell proliferation (Ki-67; clone ab16667, 
Abcam; dilution 1:100) and cell apoptosis (Cleaved Caspase-3 
(Asp175) (5A1E) ab9664S, Abcam; dilution 1:100) was exam-
ined on consecutive 4 µm FFPE sections of the neoplastic 
cores. Reactions were performed using the automated Bench-
mark XT platform (Ventana Medical Systems, Basel, Switzer-
land). Appropriate positive and negative controls were run 
concurrently.
For assessment of tumour microvascular density, CD31-pos-
itive microvessels were quantified and reported as the average 
number in 10 random fields at ×200 magnification. Ki-67 
labelling index was assessed as the average number of prolif-
erating cells in 10 random fields at ×200 magnification. 
Caspase-3 evaluation was categorised as positive or negative.
Statistical analysis
The DCR was defined by the sum of complete responses + 
partial responses + stable diseases using RECIST V.1.1. PFS was 
measured from start of treatment to date of progression or death 
from any cause. OS was defined as time from start of treatment 
to death of any cause. Patients without an event were censored at 
last follow-up. Response according to KEF (Ktrans (non-zeros) × 
EF) was defined as a drop of >70% from baseline while change 
in CD31 biomarker levels from baseline was calculated as ((8 
weeks−baseline)/baseline] ×100. CD31 change from baseline 
was explored on a continuous scale and was also dichotomised 
using the median value.
Response according to KEF parameter and the dichoto-
mised CD31 change from baseline were cross-tabulated with 
the RECIST measured DCR. χ2 or Fisher’s exact tests were 
employed to explore whether there is an association between 
them and DCR. Logistic regression was employed to produce 
ORs and 95% CIs. The PFS and OS rates were estimated 
using the Kaplan-Meier method, and survival curves were 
generated for each group. The log-rank test was used to 
compare the survival curves and a Cox proportional hazards 
model was fitted to obtain HRs and 95% CIs. The propor-
tional hazards assumption was tested with the use of Schoen-
feld residuals.
In our study, despite relatively small study cohort, the changes 
in Ktrans and KEF values were noticeably larger (eg, >50% reduc-
tion in mean and median KEF). Based on results of the 23 anal-
ysable patients evaluated by DCE-MRI in our study, our patient 
sample size by post hoc analysis (based on Wilcoxon signed-rank 
test) demonstrated 100% power to detect this difference at a 
level of significance of 0.05.
Additional methods can be found in the online appendix.
resulTs
patients’ characteristics and tissue collection
Twenty-seven treated patients (63% males) were recruited in 
the DCE-MRI PROSPECT-R trial, and a total of 143 cores 
were collected by tissue biopsies from 70 metastatic lesions 
for the current analysis. Right and left-sided primary cancers 
were equally distributed in the study population; other relevant 
patient characteristics are summarised in table 1.
Fifty-four tissue cores were obtained frombaseline biopsies 
of 27 treated (27 lesions) patients; of the 14 patients with SD 
at 8 weeks, 24 tissue cores were obtained from 12 (12 lesions) 
patients (one patient missed the biopsy due to a hospital admis-
sion secondary to chest infection and the other developed treat-
ment-related rectal wall perforation). A further 65 tissue cores 
were obtained from 23 evaluable patients (35 lesions in total; 
12 patients with two progressing lesions each) with PD (three 
patients did not complete two cycles of treatment and one came 
off due to treatment-related rectal wall perforation). There was 
89% concordance between target DCE-MRI and biopsied meta-
static lesions (see online appendix table A1). Two FFPE cores per 
patient were tested at each time point. One-hundred and nine 
plasma samples were tested to track RAS mutant clones in 21 
corresponding patients; patients were required to have at least 
one sample available at 2 months following treatment.
radiological and pathological evidence of early regorafenib 
induced anti-angiogenic effects
A significant drop in all DCE-MRI parameters was seen after 
2 weeks of treatment; median Ktrans, IAUGC60, EF and KEF 
product decreased by 27.8% (IQR 6.7–52.6), 57.7% (32.7–
67.9), 35.3% (12.4–56.2) and 58.3% (28.3–76.1) (see online 
appendix Table A2). The ROC curve analysis performed for 
the KEF showed that a 69.21% reduction from baseline had 
100% specificity and overall accuracy of 69.57%; for pragmatic 
reasons, a minimum KEF product reduction of 70% was chosen 
(see online appendix table A3). Matched tissue analysis revealed 
a strong concordance between a drop in KEF and mean vascular 
density of tissue, as measured by CD31 count obtained pretreat-
ment and at 2 months in patients with tissue and MR parameter 
data available (p=0.04) (see online appendix table A4).
Correlation of functional imaging data and CD31 staining 
with clinical parameters
After a median follow-up of 14.3 months ((95% CI 4.9—not eval-
uable (NE)), IQR 4.9—not reached), 23 patients, who had at least 
one cycle of regorafenib and a response assessment by CT scan 
at 2 months were analysable. DCR at 2 months, median PFS and 
median OS were 51.9%, 3.6 months (95% CI 1.9 to 4.2 months) 
and 5.8 months (95% CI 4.7 to 13.3 months), respectively; 77.4% 
(95% CI 54.0% to 89.9%), 48.0% (95% CI 24.1% to 68.5%) 
and 32.0% (95% CI 11.2% to 53.4%) of patients were alive at 
4, 6 and 12 months, respectively. Patients with >70% drop in 
KEF (8/27; two patients did not undergo the 2-month scan due to 
treatment-related toxicities and thus were excluded from the final 
analysis as per the study protocol) were found to have higher DCR 
(6/6 vs 0/6, p=0.05) at 2 months (see online appendix table A5), 
better PFS (HR 0.16 (95% CI 0.04 to 0.72), p=0.02), better PFS 
at 4 months (66.7% vs 23.5%) and better OS (HR 0.08 (95% CI 
0.01 to 0.63), p=0.02). For the group with >70% drop in KEF, 
6-month and 12-month OS were 100% (95% CI NE) and 75% 
(95% CI 12.8% to 96.1%), respectively compared with 27.6% 
(7.2%–53.2%) and 13.8% (1.0%–42.5%) in the <70% drop 
in KEF group (figure 2A,B; see online appendix figure A1 and 
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Figure 3 Correlation between radiological and pathological findings in the PROSPECT-R trial. Panels A–C demonstrate an example of a patient with 
durable disease control of 14 months, while panels D–F show example of a primary resistance patient (2 months). (A) Coronal DCE-MRI (central slice 
of a liver lesion) showing significant reduction in the median Ktrans(min−1) with accompanying histogram (whole lesion) at day 15 post-treatment. 
(B) Coronal CT images at baseline, best response (2 months) and at the end of treatment (14 months) for same liver lesion (left) and an abdo-pelvic 
mass (right). Patient achieved stable disease by RECIST V.1.1. (C) Matched IHC analysis demonstrating decrease and subsequent increase in tumour 
vascularity measured by staining CD31 at 2 and 14 months, respectively. (D) Coronal DCE-MRI and accompanying histogram of the liver lesion 
showing no significant reduction in the median Ktrans(min−1) at day 15 post-treatment. (E) Coronal CT images of the liver showing progression (30% 
increase) of the same target liver lesion (yellow circle) at baseline and at progression (2-month scan). (F) Matched IHC analysis demonstrating no 
change in tumour vascularity measured by staining CD31 at 2 months. Two separate progressive disease lesions were analysed to take into account 
tumour heterogeneity; however, no change in vascularity was observed in either of the biopsied lesion. CT, computed tomography; DCE, dynamic 
contrast enhanced; IHC, immunohistochemistry.
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Figure 4 Correlation between radiological, pathological and circulating biomarkers in PROSPECT-R trial. (A) Axial DCE-MRI demonstrating 
significant reduction (71%) of the median Ktrans(min−1) in the left pelvic wall recurrence, with accompanying histogram at day 15 post-regorafenib. 
(B) Three-dimensional representation of target lesion by CT performed at baseline and at week 31 (best response) demonstrating reduction in lesion 
volume. (C) FDG-PET images performed at 4 months of therapy showing residual FDG uptake, although significantly less when compared with a 
historic PET-CT performed 18 months prior to regorafenib therapy. (D) Axial CT images demonstrating a maintained RECIST V.1.1 partial response 
(45%) to regorafenib for 31 weeks. Images show representative sites of disease including left pelvis side wall, mediastinal lymphadenopathy and large 
lung metastases (yellow circles). Note is made that at the time of progression, left pelvic side wall disease progressed (28%), while the remaining 
disease had maintained partial response demonstrating the intertumoural heterogeneity in resistance to regorafenib. (E) Matched IHC analysis 
demonstrating decrease and subsequent increase in tumour vascularity measured by staining CD31 at 2 and 12 months, respectively. (F) Graphical 
representation of clonal KRAS mutation tracked by digital droplet PCR analysis of circulating tumour DNA analysis compared with CEA and total 
volume of target lesions measured RECIST V. 1.1 assessment. This demonstrates that an early drop and rise in fractional abundance of KRAS mutation 
that precedes changes in CEA, both at response and resistance to regorafenib. CEA, carcinoembryonic antigen; DCE, dynamic contrast enhanced; FDG-
PET, 18 Fluoro-deoxyglucose positron emission tomography; IHC, immunohistochemistry; MRI, magnetic resonance imaging.
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appendix table A6). In order to address the relative improvement 
in efficacy with or without KEF drop, we compared the outcomes 
of all the patients who achieved DCR; PFS was found to be 5.6 vs 
4.2 months (HR 0.30 (95% CI 0.06 to 1.49), p=0.140) and OS 
was 15.2 vs 5.8 months (HR 0.11 (95% CI 0.01 to 1.06), p=0.057) 
in this analysis. Interestingly, when the same analysis was repeated 
with the cut-off chosen by ROC analysis (69.21%), PFS (HR 0.18 
(95% CI 0.03 to 0.91), p=0.038) and OS (HR 0.11 (95% CI 0.01 
to 1.01), p=0.051) were found to be statistically significant despite 
small numbers.
A decrease in CD31 score at 2 months was associated with 
higher DCR (OR 30.0 (95% CI 2.22 to 405.98), p=0.01), better 
PFS (HR 0.13 (95% CI 0.03 to 0.52), p=0.004) and better OS 
(HR 0.30 (95% CI 0.08 to 1.06), p=0.06) (see online appendix 
figure A2). Examples of KEF drop, RECIST V. 1.1 response and 
CD31 scoring at different time points in a responder (figure 3A-C) 
and non-responder patient (figure 3D-F) are provided.
radiological and pathological analysis of proliferation and 
apoptosis following regorafenib treatment
Radiological cell kill effects of regorafenib were investigated 
by examining the changes in ADC on DW-MRI, pretreatment 
and at day 15. Matching tissue was scored for cell proliferation 
(KI-67 index) and apoptosis (caspase 3) at pretreatment and 2 
months post-therapy. Median ADC changes are described in 
online appendix table A7. The changes at 2 months in corre-
sponding tissue parameters of cell proliferation were not asso-
ciated with an improvement in DCR (OR 1.13 (95% CI 0.14 to 
9.0), p=0.91), PFS (HR 1.11 (95% CI 0.35 to 3.58), p=0.86) 
or OS (HR 0.91 (95% CI 0.19 to 4.42), p=0.91); similarly, no 
significant changes in apoptosis were observed when comparing 
baseline and 2 months treatment tissue biopsies.
liquid biopsy as a surrogate marker of response to 
regorafenib
We hypothesised that regorafenib-induced anti-angiogenic 
effects would correlate with a reduction in circulating tumour 
DNA (ctDNA). Indeed, in a patient with significant (71%) KEF 
drop after 2 weeks of treatment (figure 4A) and durable RECIST 
V. 1.1. response lasting nearly 12 months (figure 4B-D), we 
observed that the KEF reduction was correlated with CD31 drop 
(figure 4E) and associated with a rapid and marked decrease in 
KRAS G12D ctDNA which persisted for the entire duration of 
the treatment and increased again when the treatment was halted 
due to a complication (figure 4F). Intriguingly, the changes in 
carcinoembryonic antigen lagged behind the changes in ctDNA.
Figure 5 Outcome according to ctDNA drop after 2 months of treatment in the PROPSECT-R trial. Kaplan-Meier curves for progression-free survival 
(A) and overall survival (B) in patients with or without ctDNA drop, (C) spider plot demonstrating depth and duration of response to regorafenib 
(evaluated by RECIST V.1.1. criteria) according to KEF and ctDNA drop. ctDNA, circulating tumour DNA; KEF, Ktrans× enhancing fraction.
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To test this hypothesis, we analysed changes in RAS mutant 
clones in sequential liquid biopsies by ddPCR. We examined 
whether a drop in FA was associated with clinical efficacy param-
eters. We found that the loss of detectable mutant RAS clones in 
ctDNA after 4 weeks was universal to all the examined patients 
((n=21) data not shown). However, a sustained drop in ctDNA 
was observed in 47.6% of the patients at 2 months and was asso-
ciated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) 
and OS (HR 0.28 (95% CI O.07 to 1.04), p=0.06), respectively 
(figure 5A,B); PFS was 60.0% (after 4 months) and 40.0% (after 
6 months) in the groups with decrease in FA. In a multivariate 
analysis adjusting for KEF reduction, this effect was associated 
with better PFS (HR 0.23 (95% CI 0.07 to 0.75), p=0.02).
Despite the small numbers, which precluded any statistical 
analysis, it was remarkable to observe that patients with a KEF 
drop >70% and decrease in ctDNA FA had the most durable 
response to regorafenib (figure 5C).
Known biomarkers of benefit from regorafenib, toxicity 
profile and clinical outcome in the prOspeCT-r trial
A previously well-conducted study comprising 208 rego-
rafenib-treated patients demonstrated an association between 
high neutrophil, high platelet, low lymphocyte count and/or 
high neutrophil–lymphocyte ratio with prognosis.26 Due to 
the stringent inclusion criteria of our study, our data distribu-
tion did not allow to use the same cut-off used in the study by 
Del Prete and colleagues and median values were used instead. 
Notwithstanding small numbers and patient selection based on 
trial inclusion/exclusion criteria, no significant correlation with 
efficacy was found with any of the above-mentioned factors (see 
online appendix tables A8 and A9).
Moreover, other clinical factors such as PS and number of 
previous lines of treatment and toxicity were also compared 
with efficacy in a univariate analysis. Treatment-related adverse 
events were consistent with previously reported data4 and are 
summarised in online appendix tables A10 and A11. As expected, 
patients who required >50% dose reduction and those who 
received less than two cycles of regorafenib derived less benefit 
from the treatment (see online appendix tables A12).
DIsCussIOn
This proof-of-concept phase II translational research study was 
designed to assess the feasibility of combining imaging, morpho-
logical and plasma biomarkers in order to best stratify patients 
more likely to derive benefit from regorafenib in refractory 
mCRC. Our study provides the first clinical evidence that rego-
rafenib efficacy is driven by its early anti-angiogenic activity.
It is widely accepted that DCE-MRI can assess tumour 
vascular function27 ; however, establishing common method-
ology remains challenging due to the practicalities of technical 
implementation across different MR platforms and the choice 
of mathematical models for data analysis. In this study, we 
have used DCE-MRI acquisition and data analysis in line with 
international expert recommendations.27 While a large body of 
evidence supports the notion that perfusion MRI can be helpful 
in assisting dose selection and enriching patient populations more 
likely to respond in early-phase clinical trials, most studies have 
defined an observable anti-angiogenic drug effect based only on 
the limits of DCE-MRI measurement repeatability rather than 
also considering the clinical efficacy.28 Furthermore, as metas-
tases show variable degrees of necrosis and non-enhancement 
before treatment and drug-induced vascular pruning also leads 
to marked decrease in enhancement within tumours, measuring 
only the median Ktrans value is less sensitive to change due to 
averaging of the voxel values. For these reasons, we calculated 
the EF and the product of Ktrans from the enhancing voxels with 
EF (KEF), which better reflects proportional reduction of vascu-
larity within tumours.24
In this study, we have evaluated DCE-MRI in a well-defined 
study population, thus minimising the bias that may result from 
patient heterogeneity. The selected DCE-MRI parameter threshold 
applied for patient stratification is based on both a prior knowl-
edge of the measurement repeatability of our technique29 and clin-
ically validated endpoints of PFS and OS. To our knowledge, this 
is the first prospective study showing that KEF, a product of Ktrans 
and EF, can be used as a parameter of DCE-MRI with high clinical 
specificity. The KEF measurement was able to identify clinically 
meaningful responders as early as 2 weeks into treatment with 
regorafenib with 100% specificity.
The major strength of this study is that it was possible to validate 
the findings of MRI detected regorafenib-induced suppression of 
tumour vascularisation by matched tissue analysis using immunos-
taining of the endothelial marker CD31. We demonstrated that 
patients with a significant drop in CD31 score on 2-month biopsy 
had a better PFS and OS. These findings further emphasise the fact 
that drug activity is due to its anti-angiogenic properties.
It is established that genetic and non-genetic mechanisms of 
tumour heterogeneity allow functional expansion of previously 
dormant subclones under the selective pressure of chemotherapy 
in CRC cells.30 This provides a strong biological rationale for the 
use of regorafenib given its broad multikinase antitumour activity. 
However, the diversity of mechanisms of action of this drug makes 
it equally challenging to identify predictive biomarkers of clinical 
utility. Biomarker analysis of CORRECT trial data demonstrated 
that benefit from regorafenib was independent of the RAS pathway 
mutational status of the tumour, suggesting primarily an anti-an-
giogenic mechanism of action, and that liquid biopsy could be 
reliably used to characterise clonal mutations.8 We investigated 
if the circulating tumour genotype could be used as a biomarker 
of sustained anti-angiogenic activity to regorafenib by tracking 
known KRAS clonal mutations and performing serial plasma anal-
ysis by highly sensitive ddPCR methodology, at clinically relevant 
time points. A drop in FA was observed in all patients at 4 weeks 
suggesting a degree of initial anti-angiogenic activity in keeping 
with an initial drop in radiological parameters; however, this 
effect was sustained in only a proportion of patients at 2 months. 
This group of patients with persistent drop at 2 months demon-
strated better efficacy with regorafenib suggesting that sustained 
angiogenic activity was required in order to achieve maintained 
benefit from therapy. Consistent with the findings from previous 
studies,25 31 we demonstrated that ctDNA can be used for tumour 
genotyping, but beyond this we proved that it can also be used 
to monitor efficacy from regorafenib in patients showing initial 
benefit from the therapy.
Acknowledging the limitations due to small numbers of 
patients in our study, we propose that these findings should be 
validated in larger cohort of patients treated with anti-angio-
genic therapies. Due to logistical barriers, it may however not 
be possible to conduct large-scale trials scrupulously designed 
and statistically powered to address questions of biomarker 
analysis. The interpretation of our findings thus need to be 
contextualised; for example, regorafenib is currently unavailable 
free of charge to patients in the UK so the use of biomarkers 
described in this study could significantly reduce the duration of 
therapy in patients’ unlikely to derive benefit. It is conceivable 
that the health economic assessment might be more favourable 
with appropriate predictive biomarkers such as those we have 
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identified. While the search for a positive predictive biomarker 
may help better application of precision medicine, in a more 
non-resource-constrained funding environment, based on our 
findings, patients could be spared from significant drug-related 
side effects, which again would have health economic benefits.
In summary, the depth of angiogenic response measured by 
DCE-MRI and validated by matched tissue immunohistochem-
istry analysis correlates with clinical efficacy. The circulating 
tumour genotype is a potential marker of sustained anti-angiogenic 
response to regorafenib in patients with known clonal mutations.
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